U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Lung combined type small cell adenocarcinoma

MedGen UID:
231029
•Concept ID:
C1332165
•
Neoplastic Process
Synonyms: Adenocarcinoma and Small Cell Carcinoma of Lung; Adenocarcinoma and Small Cell Carcinoma of the Lung; Adenocarcinoma and Small Cell Lung Carcinoma; Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma; Combined Small Cell Lung Carcinoma and Lung Adenocarcinoma; lung combined type small cell adenocarcinoma
 
Monarch Initiative: MONDO:0000532

Definition

A lung carcinoma characterized by a combination of small cell carcinoma and adenocarcinoma. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLung combined type small cell adenocarcinoma

Professional guidelines

PubMed

Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung.
Santos ES, Rodriguez E
Clin Lung Cancer 2022 Sep;23(6):457-466. Epub 2022 Jun 21 doi: 10.1016/j.cllc.2022.06.002. PMID: 35872084
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J
Lung Cancer 2017 Oct;112:200-215. Epub 2017 Aug 10 doi: 10.1016/j.lungcan.2017.08.005. PMID: 29191596
Lung cancer: diagnosis and management.
Collins LG, Haines C, Perkel R, Enck RE
Am Fam Physician 2007 Jan 1;75(1):56-63. PMID: 17225705

Recent clinical studies

Etiology

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators
Lancet Oncol 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4 doi: 10.1016/S1470-2045(19)30634-5. PMID: 31591063
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV
J Clin Oncol 2019 Feb 1;37(4):278-285. Epub 2018 Dec 14 doi: 10.1200/JCO.18.01585. PMID: 30550363Free PMC Article
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL
Lancet Oncol 2015 Jul;16(7):830-8. Epub 2015 Jun 4 doi: 10.1016/S1470-2045(15)00026-1. PMID: 26051236
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D
J Clin Oncol 2008 Jul 20;26(21):3543-51. Epub 2008 May 27 doi: 10.1200/JCO.2007.15.0375. PMID: 18506025
Lung cancer: diagnosis and management.
Collins LG, Haines C, Perkel R, Enck RE
Am Fam Physician 2007 Jan 1;75(1):56-63. PMID: 17225705

Diagnosis

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells.
Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA
Cell Rep Med 2022 Mar 15;3(3):100554. doi: 10.1016/j.xcrm.2022.100554. PMID: 35492873Free PMC Article
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV
J Clin Oncol 2019 Feb 1;37(4):278-285. Epub 2018 Dec 14 doi: 10.1200/JCO.18.01585. PMID: 30550363Free PMC Article
Lung cancer.
Skřičková J, Kadlec B, Venclíček O, Merta Z
Cas Lek Cesk 2018 Fall;157(5):226-236. PMID: 30441934
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL
Lancet Oncol 2015 Jul;16(7):830-8. Epub 2015 Jun 4 doi: 10.1016/S1470-2045(15)00026-1. PMID: 26051236
Lung cancer: diagnosis and management.
Collins LG, Haines C, Perkel R, Enck RE
Am Fam Physician 2007 Jan 1;75(1):56-63. PMID: 17225705

Therapy

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators
Lancet Oncol 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4 doi: 10.1016/S1470-2045(19)30634-5. PMID: 31591063
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV
J Clin Oncol 2019 Feb 1;37(4):278-285. Epub 2018 Dec 14 doi: 10.1200/JCO.18.01585. PMID: 30550363Free PMC Article
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL
Lancet Oncol 2015 Jul;16(7):830-8. Epub 2015 Jun 4 doi: 10.1016/S1470-2045(15)00026-1. PMID: 26051236
Muscle wasting in cancer.
Johns N, Stephens NA, Fearon KC
Int J Biochem Cell Biol 2013 Oct;45(10):2215-29. Epub 2013 Jun 11 doi: 10.1016/j.biocel.2013.05.032. PMID: 23770121
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D
J Clin Oncol 2008 Jul 20;26(21):3543-51. Epub 2008 May 27 doi: 10.1200/JCO.2007.15.0375. PMID: 18506025

Prognosis

Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
Wang H, Yan L, Zhu Y, Sun W, Yang X, Liu X, Chi K, Huang X, Zhou L, Lin D
Hum Pathol 2023 Dec;142:81-89. Epub 2023 Sep 22 doi: 10.1016/j.humpath.2023.09.002. PMID: 37742943
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators
Lancet Oncol 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4 doi: 10.1016/S1470-2045(19)30634-5. PMID: 31591063
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV
J Clin Oncol 2019 Feb 1;37(4):278-285. Epub 2018 Dec 14 doi: 10.1200/JCO.18.01585. PMID: 30550363Free PMC Article
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J
Lung Cancer 2017 Oct;112:200-215. Epub 2017 Aug 10 doi: 10.1016/j.lungcan.2017.08.005. PMID: 29191596
Lung cancer: diagnosis and management.
Collins LG, Haines C, Perkel R, Enck RE
Am Fam Physician 2007 Jan 1;75(1):56-63. PMID: 17225705

Clinical prediction guides

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D
JAMA Oncol 2024 Feb 1;10(2):185-192. doi: 10.1001/jamaoncol.2023.5410. PMID: 38095881Free PMC Article
Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
Wang H, Yan L, Zhu Y, Sun W, Yang X, Liu X, Chi K, Huang X, Zhou L, Lin D
Hum Pathol 2023 Dec;142:81-89. Epub 2023 Sep 22 doi: 10.1016/j.humpath.2023.09.002. PMID: 37742943
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells.
Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA
Cell Rep Med 2022 Mar 15;3(3):100554. doi: 10.1016/j.xcrm.2022.100554. PMID: 35492873Free PMC Article
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J
Lung Cancer 2017 Oct;112:200-215. Epub 2017 Aug 10 doi: 10.1016/j.lungcan.2017.08.005. PMID: 29191596
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS
JAMA Oncol 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453. PMID: 27540850

Recent systematic reviews

Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P, Zhen H, Zhao H, Zhao L, Cao B
BMC Cancer 2022 Mar 26;22(1):328. doi: 10.1186/s12885-022-09444-0. PMID: 35346117Free PMC Article
Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis.
Su Y, Chen R, Han Z, Xu R, Ma L, Wufuli R, Liu H, Wang F, Ma L, Chen R, Liu J
Pathobiology 2021;88(4):267-276. Epub 2021 Jun 9 doi: 10.1159/000514386. PMID: 34107476
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J
Lung Cancer 2017 Oct;112:200-215. Epub 2017 Aug 10 doi: 10.1016/j.lungcan.2017.08.005. PMID: 29191596
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS
JAMA Oncol 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453. PMID: 27540850
Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis.
Brenner DR, Yannitsos DH, Farris MS, Johansson M, Friedenreich CM
Lung Cancer 2016 May;95:17-27. Epub 2016 Feb 4 doi: 10.1016/j.lungcan.2016.01.021. PMID: 27040847

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...